Meticulous Scrutiny
Recently, the Law Offices of Howard G. Smith initiated an investigation regarding Allarity Therapeutics, Inc. (“Allarity”) and its potential infringement of federal securities regulations. Investors holding shares in Allarity, symbolized as ALLR on the NASDAQ, are under the microscope for possible violations.
The Unveiling
On a fateful day in July 2024, Allarity came forth with revelations about receiving a Wells Notice from the U.S. Securities and Exchange Commission (SEC). This notice pertains to the company’s communications regarding discussions with the U.S. Food and Drug Administration concerning its New Drug Application (NDA) for Dovitnib. This compound had been submitted in 2021. It became known that three former executives of Allarity were also handed Wells Notices, implying that the SEC Staff is contemplating suggesting an enforcement action against the company for alleged breaches of the federal securities laws.
Seeking Answers
For investors who have a stake in Allarity, or anyone possessing relevant information or seeking clarification on these allegations, Howard G. Smith, Esquire at the Law Offices of Howard G. Smith stands as a point of contact. Questions about this matter and the rights and interests related to it can be directed to the law firm in Bensalem, Pennsylvania. Howard G. Smith can be reached by dialing (215) 638-4847 or via email at howardsmith@howardsmithlaw.com.
It is important to note that this press release may be treated as Attorney Advertising in particular jurisdictions based on the governing legal provisions and ethical codes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240724803009/en/
